ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
FACT II Acquisition Corporation

FACT II Acquisition Corporation (FACT)

9.89
0.00
(0.00%)
Cerrado 11 Enero 3:00PM
9.89
0.00
(0.00%)
Fuera de horario: 5:15PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
9.89
Postura de Compra
9.88
Postura de Venta
15.80
Volume Operado de la Acción
130,025
9.89 Rango del Día 9.90
9.85 Rango de 52 semanas 27.01
Precio Anterior
9.89
Precio de Apertura
9.90
Última hora de negociación
Volumen promedio (3 m)
24,991
Volumen financiero
US$ 1,285,947
Precio Promedio Ponderado
9.89

FACT Últimas noticias

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation PR Newswire INCLINE VILLAGE, Nev., March 24 INCLINE VILLAGE, Nev., March 24 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc...

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Facet Biotech Corporation (NASDAQ: FACT...

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for shareholders in connection to the proposed sale of the...

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”...

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Levi & Korsinsky is investigating the Board of Directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”) (NasdaqGM: FACT) for possible breaches of fiduciary duty...

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing...

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

SAN FRANCISCO, Jan. 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage cancer biotherapeutics company, today announced the appointment of Hoyoung Huh...

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

SEATTLE and REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) and Facet Biotech Corp. (NASDAQ:FACT) today announced the presentation of positive...

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.01-0.101010101019.99.99.891056259.89CS
4-17.12-63.383931877127.0127.019.85837949.88840112CS
12-17.12-63.383931877127.0127.019.85249919.88840112CS
26-17.12-63.383931877127.0127.019.85111299.88840112CS
52-17.12-63.383931877127.0127.019.8556759.88840112CS
156-17.12-63.383931877127.0127.019.8518879.88840112CS
260-17.12-63.383931877127.0127.019.8513299.88840112CS

FACT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de FACT II Acquisition?
El precio actual de las acciones de FACT II Acquisition es US$ 9.89
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de FACT II Acquisition?
FACT II Acquisition ha negociado en un rango de US$ 9.85 a US$ 27.01 durante el último año

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.83M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.72M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.61M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.69M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.83M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.31M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

FACT Discussion

Ver más
No se encontraron comentarios

Su Consulta Reciente

Delayed Upgrade Clock